When can we stop cabergoline treatment in prolactinomas?

Giovanni Vitale, Antonella Di Sarno, Francesca Rota, Gaetano Lombardi, Annamaria Colao

Research output: Contribution to journalArticlepeer-review


Prolactinoma is the most common hormone-secreting pituitary adenoma. The approach to prolactinomas has changed in the past 25 years, thanks to treatment with dopamine agonists, which is characterized by a potent prolactin inhibitory effect, a tumor-shrinking effect, and a good tolerability. Cabergoline is a new dopamine agonist with a natural long duration of action and selectivity for the D2 receptor. The authors discuss the criteria for stopping treatment with cabergoline in prolactinomas. According to their experience, they withdraw cabergoline treatment in prolactinomas after normalization of serum prolactin levels and tumor disappearance or no further reduction of tumor size on MRI during the last 12 months of follow-up.

Original languageEnglish
Pages (from-to)259-264
Number of pages6
JournalCurrent Opinion in Endocrinology and Diabetes
Issue number4
Publication statusPublished - Aug 2003

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'When can we stop cabergoline treatment in prolactinomas?'. Together they form a unique fingerprint.

Cite this